Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative Colitis: Data from ULTRA 1, 2, and 3

American Journal of Gastroenterology

Volumn 109, Issue 11, 2014, Pages 1771-1780

  Colombel, Jean Frederic ^a   Sandborn, William J ^b   Ghosh, Subrata ^c   Wolf, Douglas C ^d   Panaccione, Remo ^c   Feagan, Brian ^e   Reinisch, Walter ^f   Robinson, Anne M ^g   Lazar, Andreas ^g   Kron, Martina ^g   Huang, Bidan ^g   Skup, Martha ^g   Thakkar, Roopal B ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d Atlanta Gastroenterology Associates   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; PLACEBO; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER DISEASE; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MAINTENANCE CHEMOTHERAPY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908890256     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.242     Document Type: Article

References (17)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
2. Ordas I, Eckmann L, Talamini M et al. Ulcerative colitis. Lancet 2012; 380: 1606-19.
3. Sands BE, Kaplan GG. The role of TNF alpha in ulcerative colitis. J Clin Pharmacol 2007; 47: 930-41.
4. AbbVie. Humira (adalimumab): US prescribing information. http://www. rxabbvie.com/pdf/humira.pdf. 2013.
5. Humira - Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/21201/SPC/Humira+Pre-filled+Pen%2c+Prefilled+Syringe+and+Vial/. 2013.
6. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
7. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
8. Reinisch W, Sandborn WJ, Panaccione R et al. 52-Week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 8: 1700-9.
9. Sandborn WJ, Colombel JF, D'Haens G et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
10. Feagan BG, Sandborn WJ, Lazar A et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014; 146: 110-8.
11. Burmester GR, Panaccione R, Gordon KB et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-24.
12. Irvine EJ, Feagan B, Rochon J et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
13. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
14. Colombel JF, Sandborn WJ, Panaccione R et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1308-19.
15. Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 2013; 28: 24-30.
16. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
17. D'Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.